Treatment of acne with special emphasis on herbal remedies

Expert Review of Dermatology

Volumn 3, Issue 1, 2008, Pages 111-122

  Kumar, Anil ^a   Baboota, Sanjula ^a   Agarwal, S P ^a   Ali, Javed ^a   Ahuja, Alka ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Acne vulgaris; Ayurvedic formulation; Herbal drug delivery; Herbal therapy; Propionibacterium acnes; Systemic treatment; Topical treatment

Indexed keywords

ADAPALENE; ANTIANDROGEN; ANTIBIOTIC AGENT; AZELAIC ACID; AZITHROMYCIN; BAL 19403; BENZOYL PEROXIDE; CITRONELLAL; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; ESTROGEN; GARCINIA MANGOSTANA EXTRACT; GLUCOCORTICOID; ISOTRETINOIN; LYMECYCLINE; MINOCYCLINE; MOTRETINIDE; OCIMUM BASILICUM EXTRACT; PICOLINIC ACID; PLANT EXTRACT; RETILDEHYDE; RETINOIC ACID; RETINOID DERIVATIVE; TAZAROTENE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE VULGARIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRALGIA; AYURVEDA; BURN; COMBINATION CHEMOTHERAPY; COMEDO; CONTROLLED RELEASE FORMULATION; DAIRY PRODUCT; DEPRESSION; DESQUAMATION; DIET; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DRY SKIN; ERYTHEMA; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HERBAL MEDICINE; HORMONAL THERAPY; HUMAN; HYGIENE; HYPERPIGMENTATION; HYPOPIGMENTATION; INFLAMMATION; LIP DISEASE; MENTAL DISEASE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYALGIA; NANOENCAPSULATION; NONHUMAN; PAPULE; PATIENT ATTITUDE; PHOTOSENSITIVITY; PHOTOTOXICITY; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PRURITUS; PSEUDOMEMBRANOUS COLITIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN ABRASION; SKIN IRRITATION; STAPHYLOCOCCUS EPIDERMIDIS; SYSTEMIC THERAPY; TERATOGENESIS; TERATOGENICITY; TOPICAL TREATMENT; VAGINA CANDIDIASIS; VERTIGO; VESTIBULAR DISORDER;

EID: 40749103680     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.3.1.111     Document Type: Review

References (152)

1. Brown SK, Shalita AR. Acne vulgaris. Lancet 351, 1871-1876 (1998).
2. Cunlife WJ, Gould DJ. Prevalence of Facial acne in late adolescence and in adult. Br. J. Dermatol. 1, 1109-1110 (1979).
3. Bergfeld WF. The evaluation of management of acne: economic consideration. J. Am. Acad. Dermatol. 32, S52-S56 (1995).
4. Rothman KF, Lucky AW. Acne vulgaris. Adv. Dermatol. 8, 347-374 (1993).
5. Zouboulis CC, Eady A, Philpott M et al. 'What is the pathogenesis of acne? Exp. Dermatol. 14, 143-152 (2005).
6. Rademaker M, Garioch JJ, Simpson NB. Acne in schoolchildren: no longer a concern for dermatologist. BMJ 298, 1217-1219 (1989).
7. James J, Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J. Am. Acad. Dermatol. 49(3), S200-S210 (2003).
8. Lalla JK, Nandedkar SY, Paranjape MH, Talreja NB. Clinical trial of ayurvedic formulation in the treatment of acne vulgaris. Ethnopharmacol. 78(1), 99-102 (2001).
9. Chomnawang MT, Surassmo S, Nukoolkarn VS, Gritsanapan W. Antimicrobial effects of Thai medicinal plants against acne-inducing bacteria. J. Ethnopharmacol. 101(1-3), 330-333 (2005).
10. Koo J. The psychosocial impact of acne: Patient's perceptions. J. Am. Acad. Dermatol. 32, S26-S30 (1995).
11. Gollnick H. Current concept of the pathogenesis of acne: implication for drug treatment. Drugs 63, 1579-1596 (2003).
12. Heffernan MP, Nelson MM, Anadkat MJ. A pilot study of the safety and efficacy of picolinic acid gel in the treatment of acne vulgaris. Br. J. Dermatol. 156(3), 548-552 (2007).
13. Burton JL, Shuster S. The relationship between seborrhoea and acne vulgaris. Br. J. Dermatol. 84, 600-601 (1971).
14. Chomnawang MT Surassmo S, Nukoolkarn VS, Gritsanapan W. Effect of Garcinia mangostana on inflammation caused by Propionibacterium acnes. Fitoterapia 78(6) 401-408 (2007).
15. Jeremy AHT, Holland DB, Robert SG et al. Inflammatory events are involved in acne lesion initiation. J. Invest. Dermatol. 121, 20-27 (2003).
16. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology 196, 119-125 (1998).
17. Gollnick HPM, Zouboulis CC, Akamatsu H et al. Pathogenesis and pathogenesis-related treatment of acne. J. Dermatol. 18, 489-499 (1991).
18. Gupta AK, Gover MD. Azelaic acid (15% gel) in the treatment of acne rosacea. Int. J. Dermatol. 46(5), 533-538 (2007).
19. Tan HH, Tan AW, Barkham T, Yan XY, Zhu M. Community-based study of acne vulgaris in adolescents in Singapore. Br. J. Dermatol. 157(3), 547-551 (2007)
20. Anand Kumar BH, Sachidanand YN. Treatment of acne vulgaris with new polyherbal formulation, clarina cream and purin tablets. Indian J. Dermatol. 46(3), 138-141 (2001).
21. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int. J. Dermatol. 39, 45-50 (2000).
22. Katsambas AD, Stefanaki C, Cunliffe W. Guideline for treating acne. Clin. Dermatol. 22, 439-444 (2004).
23. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report from a global alliance to improve outcomes in acne. J. Am. Acad. Dermatol. 49, S1-S37 (2003).
24. Cooper AJ. Systemic review of Propionibacterium acnes resistance to systemic antibiotic. Med. J. Austral. 169, 259-261 (1998).
25. Rose JI, McGinely KJ, Cavalieri S et al. Antibiotic-resistant acne: lesson from Europe. Br. J. Dermatol. 148, 467-478 (2003).
26. Gopal MG, Farahana B. Effective of herbal medications in the treatment of acne vulgaris a pilot study. Indian Pract. 54(10), 723 (2001).
27. Berson DS, Shalita AR. The treatment of acne: the role of combination therapies. J. Am. Acad. Dermatol. 32(5), S31-S41 (1995).
28. Jelvehgari M, Siahi-Shadbad MR, Azarmi S, Martin GP, Nokhodchi A. The microsponge delivery system of benzoyl peroxide: preparation, characterization and release studies. Int. J. Pharm. 308, 124-132 (2006).
29. Worret WI, Fluhr JW. Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. J. Dtsch Dermatol. Ges. 4(4), 293-300 (2006).
30. Hegemann L, Toso SM, Kitay K et al. Anti-inflammatory action of benzoyl peroxide: effects on the generation of reactive oxygen species by leukocytes and the activity of protein kinase C and calmodulin. Br. J. Dermatol. 130(5), 569-575 (1994).
31. Valacchi G, Rimbac G, Saliou C et al. Effect of benzoyl peroxide on antioxidant status, NF-κB activity and interlukin-1 α gene expression in human keratinocytes. Toxicology 165(2-3), 225-234 (2001).
32. Patel VB, Misra AN, Marfatia YS. Preparation and comparative clinical evaluation of liposomal gel of benzoyl peroxide for acne. Drug Dev. Ind. Pharm. 27(8), 863-869 (2001).
33. Krautheim A, Gollnick HPM. Acne: topical treatment. Clin. Dermatol. 22, 398-407 (2004).
34. Embil K, Nacht S. The Microsponges Delivery System: a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J. Microencapsul. 13, 575-578 (1996).
35. Wester RC, Patel R, Nacht S, Leyden J, Melenders J, Maibach H. Controlled release of benzoyl peroxide from a porous microsphere polymeric system can reduce topical irritancy. J. Am. Acad. Dermatol. 24, 720-726 (1991).
36. Fyrand O, Jakobsen HB. Water besed versus alcohol based benzoyl peroxide preparation in the treatment of acne vulgaris. Dermatologica 172, 263-267 (1986).
37. Ellis CN, Leyden J, Katz HI et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis 67(Suppl. 2), 13-20 (2001).
38. Lookingbill DP, Chalker DK, Lindholm JS et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J. Am. Acad. Dermatol. 37, 590-595 (1997).
39. Swanson IK. Antibiotic resistance of Propionibacterium acne in acne vulgaris. Dermatol. Nursing 5, 359-361 (2003).
40. Shalita A. The integral role of topical and oral retinoids in the early treatment of acne. J. Eur. Acad. Derm. Venereol. 15(Suppl. 3), 43-49 (2001).
41. Cohen S, Ostrowski J, Whiting G et al. Retinoic acid receptor γ mediates topical retinoid efficacy and irritation in animal models. J. Invest. Dermatol. 104, 779-783 (1995).
42. Bergfeld WF. The evolving role of retinoids in the management of cutaneous conditions. Clinician 16, 1-32 (1998).
43. Kligman AM. The growing importance of topical retinoids in clinical dermatology: a retrospective and prospective analysis. J. Am. Acad. Dermatol. 39(Suppl. 2), S2-S7 (1998).
44. Lipson AH, Collins F, Webster WS, Multiple congenital defects associated with maternal use of topical tretinoin. Lancet 341(8856), 1352-1353 (1993).
45. Lammre EJ. Retinoic acid embryoopathy. N. Engl. J. Med. 313, 837-841 (1985).
46. Leyden J, Grove GL. Randomized facial tolerability studies comparing gel formulation of retinoids used to treat acne vulgaris. Cutis 67, 17-27 (2001).
47. Thiboutot D, Gold MH, Jarratt MT et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis 68(Suppl. 4), 10-19 (2001).
48. Schafer-Korting M, Korting HC, Ponce-Posch E. Liposomal tretinoin for uncomplicated acne vulgaris. Clin. Invest. 72, 1086-1091 (1994).
49. Ellis CN, Millikan LE, Smith EB et al. Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris. Br. J. Dermatol. 139 (Suppl. 52), 41-47 (1998).
50. Grosshans E, Marks R, Mascaro JM et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br. J. Dermatol. 139 (Suppl. 52), 26-33 (1998).
51. Sinico C, Manconi M, Peppi M, Lai F, Valenti D, Fadda AM. Liposomes as carriers for dermal delivery of tretinoin: in vitro evaluation of drug permeation and vesicle-skin interaction. J. Control. Release 103, 123-136 (2005).
52. Karlsson T, Vahlquist A, Kedishvili N et al. 13-cis retinoic acid competitively inhibbits 3 α hydroxysteoxidation by retinal dehydrogenase RoDH-4: a mechanism for anti androgenic effects in sebaceous glands. Biochem. Biophys. Res. Commun. 303, 273-278 (2003).
53. Shalita A, Weiss JS, Chalker DK et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J. Am. Acad. Dermatol. 34(3), 482-485 (1996).
54. Alirezai M, Meynadier J, Jablonska S, Czernielewski J, Verschoore M. Comparative study of the efficacy and tolerability of 0.1 and 0.03 p.100 adapalene gel and 0.025 p.100 tretinoin gel in the treatment of acne. Ann. Dermatol. Venereol. 123(3), 165-170 (1996).
55. Cunliffe WJ, Caputo R, Dreno B et al. Clinical efficacy and safety comparison of adaplene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trial. J. Am. Acad. Dermatol. 36, S126-S134 (1997).
56. Wysowski D K, Swann J, Vega A. Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J. Am. Acad. Dermatol. 46(4), 505-509 (2002).
57. Ioele G, Cione E, Risoli A, Genchi G, Ragno G. Accelerated photostability study of tretinoin and isotretinoin in liposome formulations. Int. J. Pharm. 293, 251-260 (2005).
58. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticle with skin targeting for topical delivery. Int. J. Pharmaceut. 328, 191-195 (2007).
59. Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmackokinetic data. J. Eur. Acad. Derm. Venereol. 11(Suppl. 1), S13-S19 (1998).
60. Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial. Br. J. Dermatol. 147(3), 523-527 (2002).
61. Tyoda M, Morohashi M. An overview of topical antibiotics for acne treatment. Dermatology 196(1), 1130-1134 (1998).
62. Thomas DR, Raimer S, Smith EB. Comparision of topical erythromycin 1.5% solution versus topical clindamycin phosphate 1.0% solution in the treatment of acne vulgaris. Cutis 29, 624-632 (1982).
63. Thielitz A, Helmdach M, Ropke EM et al. Lipid analysis of follicular casis from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br. J. Dermatol. 145, 19-27 (2001).
64. Strauss JS, Stranieri AM. Acne treatment with topical erythromycin and zinc: effect of Propionibacterium acne and fatty acid composition. J. Am. Acad. Dermatol. 11, 86-89 (1984).
65. Thomsen RJ, Stranieri A, Knutson D et al. Topical clindamycin treatment of acne. Arch. Dermatol. 116, 1031-1034 (1980).
66. Esterly NB, Furey NL, Flaragean LE. The effect of antimicrobial agents on leukocyte chemotaxis. 70, 51-55 (1978).
67. Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch. Dermatol. 122(8), 583-584 (1986).
68. Fisher AA. Adverse reaction topical clindamycin, erythromycin and tetracycline. Cutis 32, 415-419 (1983).
69. Milstone EB, McDonald AJ, Scholhamer CF. Pseudomembranous colitis after topical application of clindamycin. Arch. Dermatol. 117, 154-155 (1981).
70. Kurokawa I, Nishijima S, Kawabata S et al. Antimicrobial susceptibility of Propionibacterium acne isolated from acne vulgaris. Eur. J. Dermatol. 9, 25-28 (1999).
71. Leyden JJ. Current issue in antimicrobial therapy for the treatment of acne. J. Eur. Acad. Dermatol. Venereol. 15(Suppl. 3), 51-55 (2001).
72. Gupta AK, Lynde CW, Kunynetz RA et al. A randomized double-blind, multicenter, parallel group study to compare relative efficacies of the topical gel 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/ erythromycin 4% in the treatment of moderate acne vulgaris of the face. J. Cutan. Med. Surg. 7, 31-37 (2003).
73. Hoogdalem EJ, Baven TLM, Spiegel-Melsen, Terpstra IJ. Transdermal absorption of clindamycin and tretinoin from topically applied anti-acne formulation in man. Biopharm. Drug Dispos. 19, 563-569 (1998).
74. Heller S, Kellenberger J, Shapiro S. Antipropionibacterial activity of BAL19403, a novel macrolide antibiotic. Antimicrob. Agents Chemother. 51(6), 1956-1961 (2007).
75. Gupta A, Chaudhary M, Rosacea and its management: an overview. J. Eur. Acad. Dermatol. Venereol. 19, 273-285 (2005).
76. Cavicchini S, Caputo R. Long-term treatment of acne with 20% azelaic acid cream. Acta Derm. Venereol. (Suppl. 143), 40-44 (1989).
77. Bosco MC, Rapisarda A, Massazza S et al. The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 α and -1 β in macrophages. J. Immunol. 164, 3283-3291 (2000).
78. Zouboulis C, Picero-Martin J. Update and future of systemic acne treatment. Dermatology 206, 37-53 (2003).
79. Mills OH, Marples RR, Kligman AM. Acne vulgaris: oral therapy with tetracycline and topical therapy with vitamin A acid. Arch. Dermatol. 106, 200-203 (1972).
80. Humbert P, Treffe P, Chapuis JF et al. The tetracyclines in dermatology. J. Am. Acad. Dermatol. 25, 691-697 (1991).
81. Meynadier J, Alirezai M. Systemic antibiotic for acne. Dermatology 196(1), 135-139 (1998).
82. Sykes NL, Webster GF. Acne. A review of optimum management. Drugs 48, 59-70 (1994).
83. Tan HH. Antibacterial therapy for acne: a guide to selection and use of systemic agents. Am. J. Clin. Dermatol. 4, 307-314 (2003).
84. Layton AM, Cunlife WJ. Phototoxic reactions due to doxycycline: a dose-related phenomenon. Clin. Fxp. Dermatol. 18, 425-427 (1993).
85. Helms SE, Bredle DL, Zajik J et al. Oral contraceptive failure rates and oral antibiotic. J. Am. Acad. Dermatol. 36, 705-710 (1997).
86. Durani BK, Jappe U. Drug-induced Sweet's syndrome in acne caused by different tetracycline: case report and review of the literature. Br. J. Dermatol. 147, 558-562 (2002).
87. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline and doxycycline. Arch. Dermatol. 133, 1224-1230 (1997).
88. Miller ST, Stevermer JJ. Low dose doxycyclin moderately effective for acne. J. Fam. Pract. 52, 594-597 (2003).
89. Stewart DM, Torok HM, Weiss JS et al. Dose ranging efficacy of new once daily rxtended release minocycline for acne vulgaris. Cutis 78, 11-20 (2006).
90. Reisner RM. Antibiotic and anti-inflammatory therapy of acne. Dermatol. Clin. 1, 385-397 (1983).
91. Henderson CA, Cunliffe WJ. Unusual side effects in patients receiving doxycycline. Arch. Dermatol. Treat. 1, 95-96 (1989).
92. Gough A, Chapman S, Wagstaff K et al. Minocycline induced autoimmune hepatitis and systemic lupus erythermatosus like syndrome. BMJ 312, 369-372 (1996).
93. Hubbell CG, Hoobs ER, Rist T et al. Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris. Arch. Dermatol. 118, 19-22 (1982).
94. Healy E, Simpson N. Acne vulgaris. BMJ 308, 831-833 (1994).
95. Eady EA, Jones CE, Tipper JL et al. antibiotic resistant Propionibacterium in acne: need for policies to modify antibiotic usage. BMJ 306, 555-556 (1993).
96. Goulden V, Clark SM, McGeown C et al. Treatment of acne with intermittent isotretinoin. Br. J. Dermatol. 137, 106-108 (1997).
97. Layton AM, Knaggs H, Taylor J et al. Isotretinoin for acne vulgaris 10 years later: a safe and successful treatment. Br. J. Dermatol. 129, 292-296 (1993).
98. Del Rosso JQ. Recently approved systemic therapies for acne vulgaris and rosacea. Cutis 80(2), 113-120 (2007).
99. Akman A, Durusoy C, Senturk M, Koc CK, Soyturk D, Alpsoy E. Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch. Dermatol. Res. 299(10), 467-473 (2007).
100. Verros C, Rallis E. Is oral isotretinoin the treatment of choice in moderate and severe inflammatory acne vulgaris? J. Eur. Acad. Dermatol. Venereol. 21(9), 1270-1271 (2007).
101. Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoic acid: evaluation of sebum production and the clinical response in a multiple dose trial. J. Am. Acad. Dermatol. 3, 602-611 (1980).
102. Mitchell AA, Van BCM, Louik C. A pregnancy prevention program in women of childbearing age receiving isotretinoin. N. Engl. J. Med. 333, 101-106 (1995).
103. Berard A, Azoulay L, Koren, G, Blais L, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br. J. Clin. Pharmacol. 63(2), 196-205 (2007).
104. McLane J. Analysis of common side effects of isotretinoin. J. Am. Acad. Dermatol. 45, S188-S194 (2001).
105. Bremner JD, Fani N, Ali A et al. Functional brain imaging alterations in acne patients treated with isotretinoin. Am. J. Psychiatry 162, 983-991 (2005).
106. Amichai B, Sherner A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J. Am. Acad. Dermatol. 54(4), 644-646 (2006).
107. Pochi PE. Hormonal aspects of acne. J. Int. Postgrad. Med. (Suppl. 4), 7-10 (1991).
108. Thiboutot DM. Endocrinological evaluation and hormonal therapy for women with difficult acne, J. Am. Acad. Dermatol. 15(Suppl. 3), 57-61 (2001).
109. Redmond GP, Olson WH, Lippman JS et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet. Gynecol. 89, 615-622 (1997).
110. Thiboutot D, Chen WC. Update and future of hormonal therapy in acne. Dermatology 206, 57-67 (2003).
111. Stecova J, Mehnert W, Blaschke T et al. Cyproterone acetate loading to lipid nanoparticle for topical acne treatment: particle characterisation and skin uptake. Pharm. Res. 24(5), 991-1000 (2007).
112. Heymann WR. Oral contraceptives for the treatment of acne vulgaris. J. Am. Acad. Dermatol. 56(6), 1056-1057 (2007).
113. Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am. J. Clin. Dermatol. 8(4), 201-219 (2007).
114. Sato K, Matsumoto D, Iizuka F et al. Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians. Aesthetic Plast. Surg. 30(6), 689-694 (2006).
115. Perumal Sarny R. Ignacimuthu S, Sen A. Screening of 34 Indian medicinal plants for antibacterial properties. J. Ethnopharmacol. 62(2), 173-182 (1998).
116. Asai F, Tosa H, Tanaka T, Iinuma M. Xanthone from pericarp of Garcinia mangostana. Phytochemistry 39(4), 943-944 (1995).
117. Fabry W, Okemo PO, Ansorg R. Antibacterial activity of East Affican medicinal plant. J. Ethnopharmacol. 60(1), 79-84 (1998).
118. Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (tea tree) oil: a review of antimicrobial and other medicinal properties. Clin. Microbiol. Rev. 19(1), 60-62 (2006).
119. Biju SS, Ahuja A, Khar RK. Tea tree oil concentration in follicular casts after topical delivery: determination by high performance thin layer chromatography using a perfused bovine udder model. J. Pharm. Sci. 94, 240-245 (2005).
120. Biju SS, Khar RK, Ahuja A, Chowdhary R. Formulation and evaluation of an effective pH balanced topical antimicrobial product containing tea tree oil. Pharmazie 60, 208-211 (2005).
121. Bassett IB, Pannowitz DL, Bametson RS. A comparative study of tea tree oil versus benzoyal peroxide in the treatment of acne. Med. J. Aust. 153, 455-458 (1990).
122. Henley D, Lipson N, Korach K et al. Prepubertal gynecomastia linked to lavender and tea tree oil. N. Engl. J. Med. 356, 479-485 (2007).
123. Perrett CM, Evans AV, Russell-Jones R. Tea tree oil dermatitis associated with linear IgA disease. Clin. Exp. Dermatol. 28, 167-170 (2003).
124. Park J, Lee J, Jung E et al. In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp. Eur. J. Pharmacol. 496, 189-195 (2064).
125. Clark A, EI-Feraly, Li F. Antimicrobial activity of phenolic constituents of Magnolia grandiflora. J. Pharm. Sci. 70, 951-952 (1981).
126. Yang S, Hsieh M, Tsai T, Hsu S. Effector mechanism of magnolol-induced apoptosis in human lung squamous carcinoma CH27 cells. Br. J. Pharmacol. 138, 193-201 (2003).
127. Falcocchio S, Ruiz C, Pastor FIJ, Saso L, Diaz P. Propionibacterium acnes GehA lipase, an enzyme involved in acne development, can be successfully inhibited by defind natural substances. J. Mol. Catal. B Enzym. 40, 132-137 (2006).
128. Paranjpe P, Kulkarni PH. Comparative efficacy of four ayurvedic formulation in the treatment of acne vulgaris: a double-blind randomized placebo-controlled clinical evaluation. J. Ethnopharmacol. 49(3), 127-132 (1995).
129. Siddiqui S, Faizi S, Siddiqui BS. Constituents of Azadirachta indica: isolation and structure elucidation of a new antibacterial tetranortriterpenoid, mahmoodin, and a new protolimnoid, naheedin. J. Nat. Prod. 55(3), 303-310 (1992).
130. Bismas K, Chattopadhyay I, Kumar R, Banerjee RK. Biological activities and medicinal properties of neem (Azadirachta indica). Curr. Sci. 82(11), 1336-1345 (2002).
131. Qadan F, Thewaini AJ, Ali DA, Afifi R, Elkhawad A, Matalka KZ. The antimicrobial activities of Psidium guajava and Juglans regia leaf extracts to acne-developing organisms. Am. J. Chin. Med. 33(2), 197-204 (2005).
132. Nam C, Kim S, Sim Y, Chang I. Anti-acne effects of Oriental herb extracts: a novel screening method to select anti-acne agents. Skin Pharmacol. Appl. Skin Physiol. 16(2), 84-90 (2003).
133. Memory Elvin-Lewis. Should we be concerned about herbal remedies? J Ethnopharmacol. 75,141-164 (2001).
134. Faizi S, Ali M. Shamimin: a new flavonol C-glycoside from leaves of Bombax ceiba. Planta Med. 65(4), 383-385 (1999).
135. Higaki S, Hasegawa Y, Morohashi M, Takayoshi Y. The correlation of Kampo formulations and their ingredients on anti-bacterial activities against Propionibacterium acnes. J. Dermatol. 22(1), 4-9 (1995).
136. Higaki S, Nakamura M, Morohashi M, Hasegawa Y, Yamagishi T. Activity of eleven kampo formulations and eight kampo crude drugs against Propionibacterium acnes isolated from acne patients: retrospective evaluation in 1990 and 1995. J. Dermatol. 23(12), 871-875 (1996).
137. Akamatsu H, Asada Y, Horio T. Effect of Keigai-Rengyo-To, a Japanese kampo medicine, on neutrophil functions: a possible mechanism of action of keigai-rengyo-to in acne. J. Int. Med. Res. 25(5), 255-265 (1997).
138. Higaki S, Nakamura M, Morohashi M, Yamagishi T. Propionibacterium acnes biotypes and susceptibility to minocycline and Keigai-rengo-to. Int. J. Dermatol. 43(2), 103-107 (2004).
139. Higaki S, Morimatsu S, Marahashi Yamagishi T, Hasegawa Y. Susceptibility of Propionibacterium acnes, Staphylococus aureus and Staphylococcus epidermidis to 10 Kampo formulations. J. Int. Med. Res. 25(6), 318-324 (1997).
140. Higaki S, Kitagawa T, Kagoura M, Morohashi M, Yamagishi T. Relationship between Propionibacterium acnes biotypes and Jumi-haidoku-to. J. Dermatol. 27(10), 635-638 (2000).
141. Higaki S, Toyomoto T, Morohashi M. Seijobofu-to, Jumi-haidoku-to and Toki-shakuyaku-san suppress rashes and incidental symptoms in acne patients. Drugs Exp. Clin. Res. 28(5), 193-196 (2002).
142. Dharmasiri MG, Jayakody JR, Galhena G, Liyanage SS, Ratnasooriya WD. Anti-inflammatory and analgesic activities of mature fresh leaves of Vitex negundo. J. Ethnopharmacol. 87(2-3),199-206 (2003).
143. Daniele C, Thompson CJ, Pittler MH, Ernst E. Vitex agnus castus: a systematic review of adverse events. Drug Saf. 28(4), 319-332 (2005).
144. Ding X, Staudinger JL. The ratio of constitutive androstane receptor to pregnane X receptor determines the activity of guggulsterone against the Cyp2b10 promoter. J. Pharmacol Exp. Ther. 314(1), 120-127 (2005).
145. Dattner AM. From medical herbalism to phytotherapy in dermatology: back to the future. Dermatol. Ther. 16(2), 106-113 (2003).
146. Slbodnikova L, Kostalova D, Labudova D, Kotulova D, Keltmann V. Antimicrobial activity of Mahonia aquifolium crude extract and its major isolated alkaloids. Phytother. Res. 18(8), 674-676 (2004).
147. Orafidiya LO, Agbani EO, Oyedele AO et al. Preliminary clinical tests on topical preparations of Ocimum gratissimum linn leaf essential oil for the treatment of acne vulgaris. Clin. Drug Invest. 22, 313-319 (2003).
148. Choi S, Chung, M. A Review on the relationship between Aloe Vera components and their biologic effects. Semin. Integrative Med. 1, 53-62 (2003).
149. Cole L, Heard C. Skin permeation enhancement potential of Aloe Vera and a proposed mechanism of action based upon size exclusion and pull effect. Int. J. Pharmaceutics 333, 10-16 (2007).
150. Avila H, Rivero J, Herrera F et al. Cytotoxicity of a low molecular weight fraction from Aloe vera (Aloe barbadensis miller) gel. Toxicon 35, 1423-1430 (1997).
151. Orafidiya LO, Agbani EO, Oyedele AO et al. The effect of aloe vera gel on the anti-acne properties of the essential oil of Ocimum gratissimum linn leaf - a preliminary clinical investigation. In. J. Aromaherapy 14, 15-21 (2004).
152. Lertsatitthanakorn P Taweechaisupapong S, Aromdee C et al. In vitro bioactivities of essential oils used for acne control. Int. J. Aromatherapy 16, 43-49 (2006).